A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)

NCT01908829 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2174

Enrollment

INDUSTRY

Sponsor class

Conditions

Urinary Bladder Diseases
Urinary Bladder Overactive
Urologic Diseases

Interventions

DRUG: mirabegron 25 mg
DRUG: mirabegron 50 mg
DRUG: solifenacin 5 mg
DRUG: solifenacin 10 mg
DRUG: mirabegron 25 mg matching placebo
DRUG: mirabegron 50 mg matching placebo
DRUG: solifenacin 5 mg matching placebo
DRUG: solifenacin 10 mg matching placebo

Sponsor

Astellas Pharma Europe Ltd.